ロード中...
Data from a pooled post hoc analysis of 14 placebo-controlled, dapagliflozin treatment studies in patients with type 2 diabetes with and without anemia at baseline
Dapagliflozin is a highly selective sodium-glucose cotransporter 2 inhibitor associated with stabilization of estimated glomerular filtration rate (eGFR); reductions in glycated hemoglobin (HbA1c), systolic blood pressure, body weight, and albuminuria; and a small and consistent increase in hematocr...
保存先:
| 出版年: | Data Brief |
|---|---|
| 主要な著者: | , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Elsevier
2021
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8255174/ https://ncbi.nlm.nih.gov/pubmed/34258337 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.dib.2021.107237 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|